St. Joseph’s Hospital Brings New Treatment for AFib to Central Florida

A new cryoablation procedure designed to improve treatment of paroxysmal atrial fibrillation (AFib) is being offered by St. Joseph’s Hospital Heart and Vascular Institute in Tampa.

The hospital, part of BayCare Health System, participated in the research trials of the equipment used. Now, St. Joseph’s is the first hospital in Central Florida and the third in the state to perform the ablation procedure after FDA-approval in September of a specialized cardiac cryoablation catheter for the treatment of AFib.

AFib is a heart condition that occurs when the heart’s chambers are out of sync, creating irregular beating that can lead to blood clots and serious heart-related complications such as stroke or heart failure. This new technology provides physicians a wider range of tools to address pulmonary vein anatomies to help address some cases of AFib.

Interventional Cardiologist Kevin Makati, MD, performed the first procedure last month shortly after FDA approval. He was the principal investigator during the clinical trials of the equipment starting in 2020 at St. Joseph’s Hospital. Through research and participation in clinical trials, BayCare and its physicians partner with leading scientists around the world to drive medical innovation, ensuring patients and the West Central Florida and Tampa Bay communities have access to the best potential treatment options possible.

Cryoablation is a minimally invasive procedure for treating AFib in which a balloon catheter delivers cryotherapy at the opening of the pulmonary veins. Cryotherapy freezes the target tissue and creates small scars to block the irregular electrical signals that cause arrhythmia, thereby improving a patient’s chance at living free from atrial fibrillation.

“This is yet another example of how the St. Joseph’s Hospital Heart and Vascular Institute leads from the front,” said Phil Minden, St. Joseph’s Hospital president. “We are so proud to be a center where our clinicians and team have the opportunity to participate in cutting-edge technology that will help provide advanced, exceptional care to our patients.”

The new technology, named POLARx™ Cryoablation System, is designed to provide treatment of paroxysmal atrial fibrillation (AFib), an intermittent form of AFib that causes an irregular and often abnormally fast heart rate. The system features a cryoablation balloon catheter, a unique device that enables two balloon sizes – 28 mm (about 1.1 in) and 31 mm (about 1.22 in) – in one catheter. This capability promotes procedural efficiency, allows physicians to address a wider range of pulmonary vein anatomies, and helps achieve more complete tissue contact to better deliver treatment to areas of the heart where disruptive signals that cause AFib originate.

As one of the nation’s Top 50 cardiovascular hospitals as recognized by PINC AI™ and reported by Fortune, St. Joseph’s Hospital Heart and Vascular Institute is a clinical leader in the Tampa Bay area and in the country.  BayCare, with a total of 16 hospitals, hopes to offer this advanced technology at other facilities in the future.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”